Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 35 for:    "Ovarian Epithelial Cancer" | "Micronutrients"

A Study of Serum Folate Levels in Patients Treated With Olaparib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04024254
Recruitment Status : Not yet recruiting
First Posted : July 18, 2019
Last Update Posted : July 18, 2019
Sponsor:
Information provided by (Responsible Party):
Lydia Usha, Rush University Medical Center

Brief Summary:
This is a study investigating folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib to treat their advanced ovarian or breast cancer. The primary goal of this study is to determine the frequency and timing of folate deficiency, and to learn more about whether giving folic acid supplements (vitamins) will help delay or avoid deficiency in these patients. Deficiency can cause doctors to reduce or stop treatment with olaparib. In this case, patients are not getting the best treatment for their cancer due to the unwanted side effect.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Breast Cancer Folic Acid Deficiency Drug: Folic Acid Tablet Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of Serum Folate Levels in Patients Treated With Olaparib
Estimated Study Start Date : August 2019
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021


Arm Intervention/treatment
Experimental: Folic Acid
Folic Acid supplement 1 mg by mouth daily
Drug: Folic Acid Tablet
Folic Acid 1 mg by mouth daily

No Intervention: No Supplementation



Primary Outcome Measures :
  1. Frequency of Folate Deficiency [ Time Frame: Up to approximately 2 years ]
    The frequency of folate deficiency in patients with ovarian and breast cancers who are treated with olaparib will be measured.

  2. Timing of Folate Deficiency [ Time Frame: Up to approximately 2 years ]
    The timing of folate deficiency in patients with ovarian and breast cancers who are treated with olaparib will be measured.


Secondary Outcome Measures :
  1. Complete Blood Count (CBC) [ Time Frame: Up to approximately 2 years ]
    To evaluate the effect of folic acid supplementation on hemoglobin level, CBC will be measured every 2 weeks for the first 3 months, and then monthly thereafter for duration of olaparib therapy. Hematological toxicity will be assessed by utilizing CTC Version 4.0.

  2. Serum folate [ Time Frame: Up to approximately 2 years ]
    To evaluate the effect of folic acid supplementation on serum folate levels, serum folate will be measured every 2 weeks for the first 3 months, and then monthly thereafter for duration of olaparib therapy.

  3. Number of required blood tranfusions [ Time Frame: Up to approximately 2 years ]
    The number of blood transfusions during olaparib treatment will be measured.

  4. Number of olaparib dose interruptions [ Time Frame: Up to approximately 2 years ]
    The number of interruptions in olaparib treatment will be measured.

  5. Number of olaparib dose reductions [ Time Frame: Up to approximately 2 years ]
    The number of reductions in olaparib treatment will be measured.

  6. Number of olaparib discontinuations [ Time Frame: Up to approximately 2 years ]
    The number of subjects who have their olaparib treatments discontinued will be measured.

  7. Response Rate to olaparib [ Time Frame: Up to approximately 2 years ]
    The response rate will be assessed by treating physicians. The data on the response rate will be collected and correlated with hematologic toxicity, serum folate level, and folic acid supplementation.

  8. Progression-free survival (PFS) [ Time Frame: Up to approximately 2 years ]
    Investigators will compare progression free survival in Lynparza- treated patient with folate deficiency who were subsequently treated with folic acid to those who did not develop folate deficiency and did not require supplementation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to provide signed informed consent
  • Female, post-menopausal, ≥18 years of age inclusive, at the time of signing the consent form
  • Individuals who have ovarian cancer or breast cancer who are recommended to start olaparib
  • Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:
  • Haemoglobin ≥ 9 g/dL with no blood transfusion in the past 28 days
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
  • Platelet count ≥ 100 x 109/L
  • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN
  • Patients must have creatinine clearance estimated of ≥51 mL/min
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1).
  • Patients must have a life expectancy ≥ 16 weeks.
  • At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT and is suitable for repeated assessment.

Exclusion Criteria:

  • Patients with folic acid deficiency, defined as folate <7 ng/mL, or those taking folic acid supplementation within 30 days of olaparib initiation.
  • Other malignancy unless curatively treated with no evidence of disease for ≥5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma. Patients with a history of localised triple negative breast cancer may be eligible, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
  • Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.
  • Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia.
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
  • Patients with symptomatic uncontrolled brain metastases.
  • Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
  • Patients with known active hepatitis (i.e. Hepatitis B or C).
  • Any previous treatment with PARP inhibitor, including Olaparib.
  • Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
  • Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
  • Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  • Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
  • Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable).
  • Participation in another clinical study with an investigational product administered in the last 1 month
  • Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
  • Patients with a known hypersensitivity to folic acid or any of the excipients of the product.
  • Involvement in the planning and/or conduct of the study
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
  • Previous enrollment in the present study
  • Breast feeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04024254


Contacts
Layout table for location contacts
Contact: Lois Winkelman, RN 312-942-2417 Lois_Winkelman@rush.edu

Sponsors and Collaborators
Rush University Medical Center

Layout table for additonal information
Responsible Party: Lydia Usha, Associate Professor of Medicine, Rush University Medical Center
ClinicalTrials.gov Identifier: NCT04024254     History of Changes
Other Study ID Numbers: ESR-18-13807
First Posted: July 18, 2019    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Lydia Usha, Rush University Medical Center:
ovarian cancer
breast cancer
olaparib
folic acid deficiency

Additional relevant MeSH terms:
Layout table for MeSH terms
Micronutrients
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Folic Acid Deficiency
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Vitamin B Deficiency
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Folic Acid
Vitamin B Complex
Olaparib
Hematinics
Vitamins
Nutrients
Growth Substances
Physiological Effects of Drugs